Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Mar;77(5):789–796. doi: 10.1038/bjc.1998.128

Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity.

H J van Slooten 1, M J van de Vijver 1, C J van de Velde 1, J H van Dierendonck 1
PMCID: PMC2149956  PMID: 9514059

Abstract

Bcl-2 has been demonstrated to inhibit apoptosis in breast cancer cells in vitro, and the ratio between Bcl-2 and its proapoptotic homologue Bax seems to be an important determinant of cellular sensitivity to induction of apoptosis. However, little information is available on the relationship between Bcl-2 and the rate of apoptotic and necrotic cell death in breast tumours. From a series of 441 premenopausal, lymphnode-negative breast cancer patients, a subset of 49 tumours was selected in which immunostaining for the 26-kDa isoform of Bcl-2 was either absent (n = 23) or very high (n = 26). High expression of Bcl-2 was found to be strongly associated with low rates of apoptotic (P < 0.001) and necrotic cell death (P < 0.001). The mean value of the apoptotic index was 2.69%+/-1.40% in Bcl-2-negative tumours and 0.68%+/-1.00% in Bcl-2-positive tumours. Expression of the proapoptotic protein Bax correlated neither with Bcl-2 nor with the frequency of apoptotic cells. Immunostaining for the antiapoptotic Bcl-2 homologue BcI-X(L) correlated with Bcl-2 expression (P < 0.001) but not with apoptosis. High proliferation rate and high tumour grade (Bloom-Richardson) were strongly associated with absence of Bcl-2 expression (P< 0.001). p53 accumulation was associated with absence of Bcl-2 expression and increased apoptotic activity. Loss of Bcl-2 expression was strongly correlated with increased apoptotic and necrotic cell death, high proliferation rate and high tumour grade, supporting a model in which Bcl-2 not only mediates cell death, but also cell division in breast cancer tissue, and in which regulation of cell division and cell death are tightly linked.

Full text

PDF
789

Images in this article

791Figure 1
on p.791

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aihara M., Scardino P. T., Truong L. D., Wheeler T. M., Goad J. R., Yang G., Thompson T. C. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15;75(2):522–529. doi: 10.1002/1097-0142(19950115)75:2<522::aid-cncr2820750215>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  2. Bhargava V., Kell D. L., van de Rijn M., Warnke R. A. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol. 1994 Sep;145(3):535–540. [PMC free article] [PubMed] [Google Scholar]
  3. Blagosklonny M. V., Schulte T., Nguyen P., Trepel J., Neckers L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 1996 Apr 15;56(8):1851–1854. [PubMed] [Google Scholar]
  4. Bodis S., Siziopikou K. P., Schnitt S. J., Harris J. R., Fisher D. E. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer. 1996 May 1;77(9):1831–1835. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1831::AID-CNCR11>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  5. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem. 1996 May 31;271(22):12695–12698. doi: 10.1074/jbc.271.22.12695. [DOI] [PubMed] [Google Scholar]
  6. Brady H. J., Gil-Gómez G., Kirberg J., Berns A. J. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 1996 Dec 16;15(24):6991–7001. [PMC free article] [PubMed] [Google Scholar]
  7. Campos L., Rouault J. P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J. P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993 Jun 1;81(11):3091–3096. [PubMed] [Google Scholar]
  8. Chresta C. M., Masters J. R., Hickman J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 1996 Apr 15;56(8):1834–1841. [PubMed] [Google Scholar]
  9. Donaldson K. L., Goolsby G. L., Kiener P. A., Wahl A. F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ. 1994 Oct;5(10):1041–1050. [PubMed] [Google Scholar]
  10. Du M., Singh N., Husseuin A., Isaacson P. G., Pan L. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol. 1996 Apr;178(4):379–384. doi: 10.1002/(SICI)1096-9896(199604)178:4<379::AID-PATH487>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  11. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  12. Field S. J., Tsai F. Y., Kuo F., Zubiaga A. M., Kaelin W. G., Jr, Livingston D. M., Orkin S. H., Greenberg M. E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996 May 17;85(4):549–561. doi: 10.1016/s0092-8674(00)81255-6. [DOI] [PubMed] [Google Scholar]
  13. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giaccia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996 Jan 4;379(6560):88–91. doi: 10.1038/379088a0. [DOI] [PubMed] [Google Scholar]
  15. Guan R. J., Moss S. F., Arber N., Krajewski S., Reed J. C., Holt P. R. 30 KDa phosphorylated form of Bcl-2 protein in human colon. Oncogene. 1996 Jun 20;12(12):2605–2609. [PubMed] [Google Scholar]
  16. Huang Y., Ray S., Reed J. C., Ibrado A. M., Tang C., Nawabi A., Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat. 1997 Jan;42(1):73–81. doi: 10.1023/a:1005777219997. [DOI] [PubMed] [Google Scholar]
  17. Isacson C., Kessis T. D., Hedrick L., Cho K. R. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res. 1996 Feb 15;56(4):669–674. [PubMed] [Google Scholar]
  18. Joensuu H., Pylkkänen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 1994 Nov;145(5):1191–1198. [PMC free article] [PubMed] [Google Scholar]
  19. Kerr J. F., Winterford C. M., Harmon B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994 Apr 15;73(8):2013–2026. doi: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  20. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
  21. Korsmeyer S. J. Regulators of cell death. Trends Genet. 1995 Mar;11(3):101–105. doi: 10.1016/S0168-9525(00)89010-1. [DOI] [PubMed] [Google Scholar]
  22. Koshida Y., Saegusa M., Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer. 1997;75(3):367–373. doi: 10.1038/bjc.1997.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995 Oct 1;55(19):4471–4478. [PubMed] [Google Scholar]
  24. Kranenburg O., van der Eb A. J., Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996 Jan 2;15(1):46–54. [PMC free article] [PubMed] [Google Scholar]
  25. Leek R. D., Kaklamanis L., Pezzella F., Gatter K. C., Harris A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer. 1994 Jan;69(1):135–139. doi: 10.1038/bjc.1994.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lipponen P. K., Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 1994 Aug;173(4):333–339. doi: 10.1002/path.1711730408. [DOI] [PubMed] [Google Scholar]
  27. Lipponen P., Pietiläinen T., Kosma V. M., Aaltomaa S., Eskelinen M., Syrjänen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995 Sep;177(1):49–55. doi: 10.1002/path.1711770109. [DOI] [PubMed] [Google Scholar]
  28. Lu P. J., Lu Q. L., Rughetti A., Taylor-Papadimitriou J. bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells. J Cell Biol. 1995 Jun;129(5):1363–1378. doi: 10.1083/jcb.129.5.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Morgenbesser S. D., Williams B. O., Jacks T., DePinho R. A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 1994 Sep 1;371(6492):72–74. doi: 10.1038/371072a0. [DOI] [PubMed] [Google Scholar]
  30. Naik P., Karrim J., Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 1996 Sep 1;10(17):2105–2116. doi: 10.1101/gad.10.17.2105. [DOI] [PubMed] [Google Scholar]
  31. O'Reilly L. A., Huang D. C., Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 1996 Dec 16;15(24):6979–6990. [PMC free article] [PubMed] [Google Scholar]
  32. Pandey S., Wang E. Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse. J Cell Biochem. 1995 Jun;58(2):135–150. doi: 10.1002/jcb.240580203. [DOI] [PubMed] [Google Scholar]
  33. Pietenpol J. A., Papadopoulos N., Markowitz S., Willson J. K., Kinzler K. W., Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res. 1994 Jul 15;54(14):3714–3717. [PubMed] [Google Scholar]
  34. Reed J. C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994 Jan;124(1-2):1–6. doi: 10.1083/jcb.124.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sabourin J. C., Martin A., Baruch J., Truc J. B., Gompel A., Poitout P. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer. 1994 Oct 1;59(1):1–6. doi: 10.1002/ijc.2910590102. [DOI] [PubMed] [Google Scholar]
  36. Schneider H. J., Sampson S. A., Cunningham D., Norman A. R., Andreyev H. J., Tilsed J. V., Clarke P. A. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer. 1997;75(3):427–431. doi: 10.1038/bjc.1997.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shi L., Nishioka W. K., Th'ng J., Bradbury E. M., Litchfield D. W., Greenberg A. H. Premature p34cdc2 activation required for apoptosis. Science. 1994 Feb 25;263(5150):1143–1145. doi: 10.1126/science.8108732. [DOI] [PubMed] [Google Scholar]
  38. Shimizu S., Eguchi Y., Kamiike W., Waguri S., Uchiyama Y., Matsuda H., Tsujimoto Y. Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Oncogene. 1996 May 16;12(10):2045–2050. [PubMed] [Google Scholar]
  39. Shimizu S., Eguchi Y., Kosaka H., Kamiike W., Matsuda H., Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature. 1995 Apr 27;374(6525):811–813. doi: 10.1038/374811a0. [DOI] [PubMed] [Google Scholar]
  40. Shimizu T., O'Connor P. M., Kohn K. W., Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 1995 Jan 15;55(2):228–231. [PubMed] [Google Scholar]
  41. Shoji Y., Saegusa M., Takano Y., Ohbu M., Okayasu I. Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol. 1996 Feb;49(2):134–138. doi: 10.1136/jcp.49.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Silvestrini R., Benini E., Veneroni S., Daidone M. G., Tomasic G., Squicciarini P., Salvadori B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996 May;14(5):1604–1610. doi: 10.1200/JCO.1996.14.5.1604. [DOI] [PubMed] [Google Scholar]
  43. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  44. Siziopikou K. P., Prioleau J. E., Harris J. R., Schnitt S. J. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer. 1996 Feb 1;77(3):499–506. doi: 10.1002/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  45. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  46. Teixeira C., Reed J. C., Pratt M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995 Sep 1;55(17):3902–3907. [PubMed] [Google Scholar]
  47. Theodorakis P., D'Sa-Eipper C., Subramanian T., Chinnadurai G. Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. Oncogene. 1996 Apr 18;12(8):1707–1713. [PubMed] [Google Scholar]
  48. Wang J., Guo K., Wills K. N., Walsh K. Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res. 1997 Feb 1;57(3):351–354. [PubMed] [Google Scholar]
  49. Wang Q., Worland P. J., Clark J. L., Carlson B. A., Sausville E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. 1995 Aug;6(8):927–936. [PubMed] [Google Scholar]
  50. Wang T. T., Phang J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995 Jun 15;55(12):2487–2489. [PubMed] [Google Scholar]
  51. Williams B. O., Remington L., Albert D. M., Mukai S., Bronson R. T., Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994 Aug;7(4):480–484. doi: 10.1038/ng0894-480. [DOI] [PubMed] [Google Scholar]
  52. Yao S. L., Akhtar A. J., McKenna K. A., Bedi G. C., Sidransky D., Mabry M., Ravi R., Collector M. I., Jones R. J., Sharkis S. J. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med. 1996 Oct;2(10):1140–1143. doi: 10.1038/nm1096-1140. [DOI] [PubMed] [Google Scholar]
  53. Yao S. L., McKenna K. A., Sharkis S. J., Bedi A. Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. Cancer Res. 1996 Oct 15;56(20):4551–4555. [PubMed] [Google Scholar]
  54. Yin X. M., Oltvai Z. N., Korsmeyer S. J. Heterodimerization with Bax is required for Bcl-2 to repress cell death. Curr Top Microbiol Immunol. 1995;194:331–338. doi: 10.1007/978-3-642-79275-5_38. [DOI] [PubMed] [Google Scholar]
  55. Zörnig M., Evan G. I. Cell cycle: on target with Myc. Curr Biol. 1996 Dec 1;6(12):1553–1556. doi: 10.1016/s0960-9822(02)70769-0. [DOI] [PubMed] [Google Scholar]
  56. van Slooten H. J., Clahsen P. C., van Dierendonck J. H., Duval C., Pallud C., Mandard A. M., Delobelle-Deroide A., van de Velde C. J., van de Vijver M. J. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996 Jul;74(1):78–85. doi: 10.1038/bjc.1996.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES